Immune cell study in melanoma patients
Part of Cancer, Skin clinical trials.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have melanoma (a type of skin cancer) at any stage (I, II, III, or IV).
- Your melanoma is not in the eye (ocular melanoma).
- You are able to give permission (sign a consent form) to be part of the study.
- You are not under a legal guardianship, in prison, or in a situation where you cannot make your own medical decisions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This trial is looking at a protein called CD160 on immune cells (NK cells) in melanoma patients. The goal is to understand if this protein can be a target for new treatments. By studying your blood and tumor samples, researchers hope to find better ways to treat advanced melanoma.
This trial studies how your immune system “profiles” change while you’re treated with immunotherapy for melanoma. Results may help doctors better understand who benefits from treatment and when.
This trial tests a special type of immune cells (gamma-delta T cells) given with either interferon or a PD-1 inhibitor for people with stage III-IV melanoma that can be removed with surgery. The goal is to see if this combination helps the immune system fight the cancer and prevent it from coming back.
This trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes). The cells are taken from a tumor sample, multiplied in a lab, and given back to you to help fight the cancer. It's for people with melanoma that has not responded to standard immunotherapy.
This trial is testing a new way to predict which immunotherapy might work best for your cancer. It uses a sample of your tumor to look for personal markers, so your treatment can be tailored to you.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.